Hinge Health, Inc. 2025 Annual Report: In-Depth Analysis for Investors

Summary of Key Points

• Hinge Health, Inc. (“HNGE”) is listed on the New York Stock Exchange under the ticker HNGE.
• The company reported a significant net loss of \$528.3 million for the year ended December 31, 2025, compared to a net loss of \$11.9 million in 2024, highlighting a sharp increase in losses.
• Shares Outstanding: As of February 23, 2026, there were 55,816,216 shares of Class A common stock, 22,947,024 shares of Class B common stock, and 2,581,837 shares of Series E redeemable convertible preferred stock outstanding.
• Public Float: The aggregate market value of publicly held shares as of June 30, 2025, was approximately \$1.5 billion.
• Hinge Health is a non-accelerated filer, smaller reporting company, and an emerging growth company, which means it is subject to less stringent SEC reporting requirements but also indicates the company is still in an early phase of public market development.
• The company operates in a highly regulated industry and faces risks related to healthcare regulations, technology, and market competition.

Key Issues and Potential Price-Moving Disclosures

1. Substantial Increase in Net Losses

Hinge Health’s net loss ballooned from \$11.9 million in 2024 to \$528.3 million in 2025. This substantial jump in losses is a major point for investors. The report suggests that the company anticipates continued high expenses as it invests in growth initiatives, regulatory compliance, technology, and operations as a public company. If these investments do not generate the expected growth or efficiencies, the losses could continue or even worsen.

Shareholders should be aware that such a steep increase in losses may impact investor confidence and could be a negative catalyst for the share price, especially if the market believes the company’s growth is not sustainable or not translating into profitability.

2. Growth Initiatives and Execution Risks

Hinge Health is implementing various growth strategies, including expanding its platform, developing new programs and products, and investing in international markets. However, management openly acknowledges that these initiatives are risky and based on assumptions that may prove inaccurate. There is no guarantee the anticipated benefits will materialize, and the company might incur higher-than-expected costs or fail to achieve growth targets or cost savings.

Failure to deliver on its growth plans or to adequately manage increased expenses could negatively impact Hinge Health’s stock price.

3. Revenue Recognition and Pricing Model Changes

The company is transitioning to an “engagement-based” pricing model, which may take longer to implement and the results may be unpredictable. Delays, implementation difficulties, or a negative impact on revenue from existing clients could result from this change. Additionally, because revenue is recognized ratably over annual subscriptions, any decline in new sales or renewals might not appear immediately in the reported revenue, but could cause significant declines in future periods.

This transition poses a risk to revenue stability and predictability, and investors should monitor quarterly results closely for signs of revenue deceleration.

4. Regulatory and Legal Risks

Hinge Health operates in a heavily regulated sector. Changes in U.S. or foreign healthcare regulatory environments, particularly regarding telehealth and AI in healthcare, could increase compliance costs or limit the company’s ability to operate or expand. The company is also subject to FDA oversight for its products; changes in FDA enforcement or new regulations could materially affect its operations.

Any negative regulatory developments or compliance failures could lead to increased costs, legal liabilities, or operational restrictions, all of which would likely be negative for the stock.

5. Dual-Class Share Structure and Voting Control

Hinge Health has a dual-class share structure, concentrating voting control with Class B stockholders (notably the founders, Daniel Perez and Gabriel Mecklenburg, and their affiliates) and Series E preferred holders. This structure significantly limits the influence of Class A shareholders on corporate matters, including director elections and major transactions.

This arrangement may be a concern for some investors and can affect governance perceptions, potentially impacting the valuation and attractiveness of the company to institutional investors.

6. Fluctuating Results and Seasonality

The company’s results fluctuate significantly due to the cyclical and seasonal nature of its business. Most new contracts are secured in the third and fourth quarters, with launches in the following year. Macroeconomic conditions may exacerbate these fluctuations, and the company warns that it may not always meet analyst or investor expectations, which could negatively impact the stock price.

7. Share Count and Dilution Risk

With over 55 million Class A shares, nearly 23 million Class B shares, and over 2.5 million Series E preferred shares outstanding, there is a risk of future dilution for common shareholders, especially if the company raises additional capital to fund ongoing losses or growth initiatives.

Other Noteworthy Points

• Hinge Health’s principal executive offices are located at 455 Market Street, Suite 700, San Francisco, CA, and its website is www.hingehealth.com.
• The company communicates material information through SEC filings, its investor website, press releases, and social media. Investors are encouraged to monitor these channels for updates.
• Portions of the 2026 proxy statement will be incorporated into the 10-K by reference.

Risks Summary for Shareholders

• Potential for continued or increasing net losses.
• Ability to effectively execute and benefit from growth strategies is uncertain.
• Revenue fluctuations due to pricing model changes and seasonality.
• Significant regulatory and legal risks, especially with evolving telehealth and AI regulations.
• Dual-class share structure limits shareholder influence.
• Potential dilution from additional share issuances.
• General macroeconomic risks could further exacerbate results.

Conclusion

Hinge Health’s 2025 Annual Report reveals substantial financial and operational risks, ongoing heavy investments in growth, and significant regulatory exposure. While the company is pursuing ambitious expansion and product development strategies, execution risk is high, and the path to profitability remains uncertain. The dramatic increase in net losses and the dual-class share structure concentrating voting power among founders and preferred holders are especially noteworthy for shareholders and could influence the company’s share price and market perception in the near- to medium-term.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own due diligence or consult a financial advisor before making investment decisions. All forward-looking statements are subject to risks and uncertainties as outlined by Hinge Health, Inc. in its SEC filings.

View Hinge Health, Inc. Historical chart here